It has been previously suggested that inherited thyroxine-binding globulin (TBG) abnormalities in man may be due to mutations at a single X-chromosome-linked locus controlling TBG synthesis. However, abnormalities in TBG degradation have not been excluded. The availability of purified human TBG and its successful labeling with radioiodide allowed us to examine such possibility. Human TBG was purified by affinity chromatography, labeled under sterile conditions with 131I or 125I,, and mixed with [125I]thyroxine (T4) or [131I]T4, respectively, before their intravenous injection. Blood and urine samples were collected over a 10-day period, and the turnover parameters were calculated. In eight normal volunteers mean values +/-SD for TBG and T4 respectively, were as follows: Half time (t1/2) 5.3 +/-0.4 and 7.0 +/-0.6 days; distribution space (DS) 7.2 +/-1.0 and 10.8 +/-1.2 liters; and total daily degradation (D) 0.211 +/-0.053 and 0.088 +/-0.011 mumol/day. In all subjects, t1/2 of TBG was shorter than that of T4; and the DS was smaller. 2.4 mol of TBG was degraded for each mole of T4. In five of six subjects from four families, comprising hemizygous and heterozygous carriers of TBG absence, decrease, and excess, the t1/2 and DS for TBG were within the normal range. A B S T R A C T It has been previously suggested that inherited thyroxine-binding globulin (TBG) abnormalities in man may be due to mutations at a single X-chromosome-linked locus controlling TBG synthesis. However, abnormalities in TBG degradation have not been excluded. The availability of purified human TBG and its successful labeling with radioiodide allowed us to examine such possibility.
INTRODUCTION
Thyroxine-binding globulin (TBG),' a serum protein migrating electrophoretically, in the inter-a-globulin zone, is the major circulating protein in man involved in thyroid hormone transport. Based on experimental evidence, it has been assumed that this protein plays only a passive role in thyroid hormone homeostasis. Indeed, in the steady state, persons with either inherited or acquired TBG abnormalities, such as with adminis1Abbreviations used in this paper: D, total daily degradation; DS, distribution space; FTI, free T4 index; k, fractional turnover rate; NHSA, normal human serum albumin; R-T4, resin T4 uptake; T4, thyroxine; TTa, serum total triiodothyronine; TT4, serum total T4; TBG, thyroxine-binding globulin; TP, serum total protein; TSH, thyroid-stimulating hormone.
The Journal of Clinical Investigation Volume 57 February 1976-485-495 485 tration of estrogens or androgens, are euthyroid and have a normal total daily degradation (D) of thyroxine (T4) despite gross alterations in the concentration of total serum T4 (1) (2) (3) (4) . The observed changes in T4 kinetics seem to be related to changes in the fractional turnover rate and/or the extrathyroidal T4 pool associated with the increased or decreased total T4-binding capacity of TBG in serum (5) . Though some reports have indicated that the free T4 concentration may be altered in the serum of subj ects with changes in the T4 capacity of TBG (6) (7) (8) , the bulk of evidence and the hormone kinetic studies suggest that the free T4 level in serum remains within the normal range and that it determines the thyroid hormone-dependent metabolic status of the subjects.
Previous work from this laboratory has shown that in subjects with either increased or decreased concentration of TBG in serum due to X-chromosome-linked abnormalities, TBG is identical to that in normal persons, electrophoretically, immunologically, in its affinity for T., and by heat inactivation (3) . Other laboratories have confirmed that TBG content measured by immunologic techniques in patients with alterations in the binding capacity to TBG is identical to that quantitated by T4 saturation techniques (3, 9, 10) . Furthermore, no abnormal substances interfering with T4 binding to TBG have been demonstrated (11, 12) . On the basis of such data, it was assumed that the most likely genetic mechanism producing X-linked TBG abnormalities in man is mutation at a single locus controlling TBG synthesis (3) . However, the possibility of alterations in the degradation rate of TBG has not been examined. The development of techniques for the purification and iodine labeling of human TBG suitable for intravenous administration provided us with the opportunity to study this possibility. Furthermore, this technique lent itself to an examination of the mechanism of acquired alterations in TBG capacity ( 13, 14) .
This report presents data on the kinetics of TBG and T4 metabolism derived from the simultaneous intravenous administration of tracer amounts of T4 and TBG labeled with different iodine isotopes. The results lead to the conclusion that the fractional turnover rate of TBG, but not of T4, is normal in X-chromosome-linked TBG abnormalities. Acquired changes in the TBG capacity, however, may be due in part to changes in the fractional turnover rate of TBG. METHODS
Laboratory materials and methods
A single preparation of human TBG purified from pooled blood bank serum by affinity chromatography (15, 16) was used. This preparation was Australia antigen negative. Radioiodination using 'I or 'I was carried out by the chloramine-T method as previously described (17) , but under sterile conditions. Sterile Sephadex columns (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) and collecting tubes were used for the separation of the iodo-TBG from unreacted iodide. The first peak fraction of iodo-TBG was at least 95%o precipitable with TCA and complexed to an extent of 90%o with an excess of specific rabbit antihuman TBG serum (17) . Labeled TBG preparations varied in their mean iodine content from 0.8 to 4.8 atoms of iodine per molecule of TBG. An aliquot of the iodo-TBG was removed by sterile capillary and diluted in normal saline containing 5% salt-poor normal human serum albumin (NHSA, Cutter Laboratories, Berkeley, Calif.). The final amount of "'I-TBG injected was 30-35 uCi/2 ml and that of "I-TBG was 5-6.5 jACi/2 ml. Depending upon the specific radioactivity of the preparation, 20-80 Al of iodo-TBG was needed to achieve this concentration.
[ To ascertain further the safety of the iodo-TBG preparation for human use, the first turnover study was performed in a single volunteer (E. H.) utilizing "'I-TBG only. Blood was obtained before injection, and thereafter at weekly intervals for 6 wk, and at monthly intervals for 6 mo for the determination of total proteins, albumin, total bilirubin, lactic dehydrogenase, glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, creatinine phosphokinase, alkaline phosphatase, Ca, P, Na, K, C1, C02, glucose, creatinine, blood urea nitrogen, cholesterol, total T4, free T4 index, thyroid-stimulating hormone, TBG capacity, prothrombin time, and complete blood count including differential, platelets, and reticulocytes. Urine samples were also obtained for routine analyses. The subject was kept under observation in the Clinical Research Center although he carried out his usual activities as laboratory technician during the day. Vital signs, including temperature, were obtained twice daily and periodic physical examinations were performed. There was no evidence of untoward effects by physical examination. Vital signs and blood chemistries remained within normal limits except during a bout of viral pharyngitis associated with sore throat, cervical lymphadenopathy, temperature of up to 38.1'C, tachycardia, and lymphocytosis which lasted for 3 days and occurred during the 7th wk after administration of the 'I-TBG. Iodo through the study period. Blood samples were obtained from the contralateral arm before the injection and at 5 min and at daily intervals for 10-11 days after the injection. All samples were aliquoted into counting vials and were kept frozen at -20'C until termination of the sample collection. The remaining serum from each sample was used for the measurement of total protein, total T4, free T4 index, and thyroid-stimulating hormone. 2 ml of serum from each sample was counted along with appropriate standards for 10 min in a Nuclear-Chicago 3-inch crystal dual-channel, well-type scintillation spectrometer (Nuclear-Chicago Corp., Des Plaines, Ill.), both before and after TCA precipitation. Corrections were made for the contribution of 'I to the reading in the 'I channel. Error due to decay of the isotopes during the counting interval was eliminated by repeat counting of all samples and standards in reverse order. A 2-ml aliquot of serum obtained before administration of the isotope was used for determination of the background and another 2-ml aliquot, after addition of 0.1% of the injected dose, as a standard.
In some patients 24-h urine samples were also obtained. Urine samples were placed in plastic bottles and kept at 4VC during the 24-h collection. The volume was measured, and 30-ml aliquots were sealed in counting vials and frozen at -200C. At the termination of the turnover study, all vials were counted together, along with appropriate standards prepared in identical volume and vials. To ascertain the completeness of each 24-h urine collection, the creatinine content was determined.
Data from the serum disappearance of TCA-precipitable 'I and '2I activity was used to calculate the ti, fractional turnover rates (k), distribution spaces (DS), and total daily degradations (D) of TBG and To. All data were corrected for diurnal changes in serum protein concentration as previously described (18), and analyzed by the method of single compartment kinetics. Slopes of the curves and intercepts were calculated by the least-squares method, utilizing an Olivetti P-602 microcomputer (Olivetti Underwood Corp., N. Y.). Previous studies have shown that, at all times, more than 95% of the serum radioactivity derived from an intravenous injection of labeled TBG to rabbits was both antibody and TCA precipitable and migrated electrophoretically as authentic iodo-TBG (17) . Similarly, the percent radioactivity precipitable with TCA and with a specific TBG antiserum, or migrating electrophoretically as intact iodo-TBG was comparable when labeled TBG was incubated for up to 9 days at 370C in the presence of sterile human serum. In some instances, the k of labeled TBG and T. were also calculated from data on the urinary excretion of the isotopes. The percent of the dose cleared each day was derived from the ratio of the percent dose excreted on that day and the percent dose retained. The latter was obtained by subtracting the cumulative percent dose excreted for each 24-h period. The k's calculated for each day, beginning with day 3 after injection, were then averaged. More than 95% of the isotopic content in urine was TCA soluble.
Tests of thyroid function. Total T4 (TT4) concentration in serum was determined by competitive-binding assay, and the resin T4 uptake (R-T4), and free To index (FTI) as previously described (19) . Serum total triiodothyronine (TTs) and thyroid-stimulating hormone (TSH) were measured by radioimmunoassay (20, 21) . TBG was measured by the single T4 load ion-exchange resin method (14) and results are expressed either as the maximal Ti-binding capacity in lsg T4/100 ml or as micromolar concentration of TBG. The TBG index was calculated from the ratio of the R-T4, expressed as percent of normal control, and the TT4 (22) . Serum total proteins (TP) were measured using a T.C. refractometer (American Optical Corp., Buffalo, N. Y.).
Clinical material
Normal subjects. Eight normal volunteers, six males and two females, 1944-yr old, in good health, and with no past or family history of thyroid illness were studied.
Subjects with inherited TBG abnormalities. Three were subjects from a family with TBG absence previously described (11) . One of them, (Mi. P.) a 21-yr-old phenotypic female with XO Turner's syndrome, was taking estrogens (Enovid, 5 mg/day) but had no detectable T4 binding in the inter-a-globulin region. Two TBG-T& turnover studies were performed approximately 4 mo apart. In one study 'I-TBG was used and in the other 'I-TBG. The two other members of the family were her mother (L. P.) and sister (P. R.), both heterozygous with decreased serum TBG concentration (3, 11) . There was no evidence of thyroid dysfunction or goiter in any member of this family.
A male (Or. W.) with decreased serum TBG concentration, thyrotoxicosis, and mild diabetes mellitus from an unrelated family was also studied. Sera from 17 members of the family were analyzed for TT4, FTI, and TBG capacity. Of 15 blood relatives tested, 8 (3 males and 5 females) had decreased TBG capacity and 7 had normal TBG capacity. Five sons of three affected fathers were normal, and all five daughters of three affected males had a reduction in the TBG capacity. The TBG capacity of the four affected males ranged from 6.4 to 8.0 gg T4/100 ml, and that of the five affected females ranged from 10.5 to 12.8 jug T4/100 ml. The data satisfy all criteria for an Xchromosome-linked mode of inheritance. Details, including a pedigree of this family has been presented (23), and will be published elsewhere. While thyrotoxic, the propositus Or. W. had a TBG capacity of 6.8 jg T4/100 ml, a TT4 of 5.7 jsg/100 ml, and FTI of 14.1.' 6 mo after successful treatment with 'I, the TBG capacity remained in the pretreatment range of 7.1 Aug T4/100 ml while the TT, was 3.3 ug/100 ml, and the FTI was 6.1.
Two unrelated male patients with inherited TBG excess were also studied. One (W. N.) was the propositus of "family N" previously reported and compatible with Xchromosome-linked mode of inheritance (3). The other patient was D. No., and propositus of "family No," not previously reported. Blood samples could be obtained from five additional members of this family, four blood relatives, and one by marriage. All four blood relatives including the mother, a sister, an aunt, and a niece were most likely affected heterozygotes as evidenced by the less marked elevation in the TBG capacities and TBG indexes when compared to the hemizygous affected propositus (Table I and Fig. 1 ). Although there were no available male offspring of affected males to prove X-chromosome linkage, the data available are not incompatible with such a mode of inheritance. The FTI was normal in all members of the family tested, and there was no evidence of thyroid disease in blood relatives.
Acquired reduction in TBG capacity. M. K. had multiple myeloma of the IgG K-type, diagnosed 5 yr before this study. Her course was complicated by hypierviscosity requiring repeated plasmaphoreses, multiple osteolytic lesions 'Normal values, TBG, 16-24 ,ug T4/100 ml; TT4, 4.2-9.4 4lg/100 ml; FTI, 3.6-9.3.
Abnormal Rate of TBG Synthesis in Inherited TBG Abnormalities faster than that of T4 (P < 0.0001). This was true when calculated from either the plasma disappearance of the TCA-precipitable activity or the urinary excretion of the isotopes (Fig. 2) . Also, the DS of TBG was smaller than that of T4 (P < 0.0001). In average the D of TBG was 2.4-fold greater (mole per mole) than that of T4 (P < 0.0001).
One normal subject, E. H., was studied twice 8 mo apart. A variation of 24% in both the ti and DS was observed between the two studies. The reason for such a discrepancy is unclear and does not seem to be the rule since in another patient (Mi. P.) the differences in the TBG ti and DS, between two studies performed 4 mo apart, were only 4 and 2%, respectively. Furthermore, no discrepancies were found in the TBG kinetic data of E. H. when 'I-TBG and "3I-TBG, labeled with an average of 0.8 and 4.8 atoms I/molecule, respectively, were administered simultaneously (Table II) . Similar results have been obtained in rabbits (17) .
TBG and T4 metabolism in X-linked inherited TBG abnormalities. Studies were performed in six subjects from four families with TBG abnormalities, exhibiting in the hemizygous affected state total absence, decrease, or excess in serum TBG. Heterozygotes for the trait were also studied. Data presented in Table II indicate that with a single exception (L. P.), the k of TBG in the subjects studied was within 2 SD of normal. The DS of TBG was also within 2 SD of the normal mean except in Mi. P., a patient of short stature, in whom a DS of 56% the normal mean was proportional to her smaller body weight of 52% the normal mean. The D of TBG, however, varied strikingly from subject to subject but remained proportional to the serum TBG concentration (Fig. 3) . Thus the defect is compatible with an abnormality in TBG synthesis. With the exception of the thyrotoxic patient, Or. W., T4 kinetics were compatible with changes in the extrathyroidal T4 pool size. As previously shown, an inverse correlation exists between the DS of T4 and the TBG concentration due to a shift in the relative distribution of the extrathyroidal T4 between the vascular and extravascular compartments. This finding has been previously summarized (3, 5) . Furthermore, as expected, the D of the hormone in the euthyroid patients was normal as was the FTI.
TBG and To metabolism in acquired TBG abnormality. A single patient with profound decrease in the TBG capacity (M. K.), suffering from multiple myeloma, was studied. Investigation of the famly (see Clini- cal Material) failed to reveal inherited TBG abnormality. As shown in Table II k values calculated from urinary excretion data are in parentheses.
E. H. had two TBG turnover studies 8 mo apart; one was done with 13I-TBG, and the second with simultaneous injection of l13I-TBG and 125I-TBG. Mi. P. had two TBG-T4 turnover studies 4 mo apart. The isotopes used in the second study were reversed in comparison to those used in the initial study.
Isotope used for labeling of Ti and TBG appears as asterisk next to the k value. *, 181I; t, 12I. ascribed to treatment with Halotestin since no significant changes were observed after discontinuation of the hormone (see Clinical Material).
TBG and T4 metabolism in thyrotoxicosis and hypothyroidism. Three subjects with serum tests compatible with thyrotoxicosis and three with hypothyroidism were studied (Table II) . One (Or. W.) had associated inherited decrease in serum TBG concentration which did not change significantly after achievement of euthyroidism (see Clinical Material). Thus, with the exception of Or. W., the two thyrotoxic patients had a TBG ti below 2 SD of normal. One of them (A. F.) also had reduced TBG, and T4 DS and body weight. Only one hypothyroid patient (K. W.) had a prolonged TBG ti as well as increased TBG DS. In another (J. A.) only the DS of TBG was reduced. It should be noted, however, that in both thyrotoxic and hypothyroid patients the serum concentration and D of TBG remained within the range found in normal persons. Furthermore, two of the hypothyroid patients were asymptomatic and had a normal ti of T4, possibly owing to the short duration of the hormonal deficiency. The D of T4 was compatible with the patients' diagnoses.
TBG and T. metabolism in patients with other than thyroid pathology. Six patients with a variety of unrelated conditions were studied and their data are shown in Table II . The TBG ti was decreased in three patients (V. U., A. M., and A. McG.), and was normal in the remaining three. The TBG DS was increased in two of the patients with decreased TBG ti (A. M. and A. McG) and in another patient S. W. It should be noted, however, that the D of TBG was increased in all patients except one, (C. G.), in whom all parameters of TBG metabolism were normal. The augmented D of TBG is due to a combination of abnormalities including increased serum TBG concentration, increased TBG DS, and accelerated TBG ti. Only in two patients (A. M. and A. McG.), in addition to M. K., the accelerated D of TBG was disproportionate to the serum TBG concentration (Fig. 3) , thus suggesting an abnormality in TBG degradation in addition to synthesis. Only one patient (A. M.) was taking estrogens. The other patient (P. D.), treated with an identical dose of estrogens, had a proportional increase in both D and serum concentration of TBG (Fig. 3) .
Because extravascular sequestration of serum proteins may have affected the metabolism of TBG, data on TP, TT4, TBG capacity, and FTI in pleural fluid obtained by thoracentesis from A. M. simultaneously with a serum sample is shown in Table III Studies on 34 families with inherited TBG abnormalities have been reported so far. We have herein described two additional families. According to the concentration of TBG in serum in affected males, the families could be subdivided into three categories: absence of TBG (13 families), low TBG (16 families), and high TBG (7 families). We have previously analyzed published data on 24 families from which it was concluded that although only in one-third of the families was X-chromosome-linked transmission suggested by the authors, the remaining kindreds showed no evidence of incompatibility with such mode of inheritance (3). With a single exception (12), a similar conclusion can be drawn from the analyses of 10 pedigrees with TBG abnormalities published since our previous review (7, 8, 12, (28) (29) (30) (31) (32) (33) and from the two new families presented. The family in question included an XX female, brother, and son with undetectable serum TBG, reduced TBG in a daughter, and normal TBG in the parents (12) . Though various speculations to explain this observation were offered by the authors, a convincing explanation is not forthcoming.
In this study the metabolism of TBG and T4 was evaluated in six members from four unrelated families with absent, low, and high serum TBG concentration, compatible with X-chromosome-linked inheritance. The k of TBG in a TBG-deficient hemizygous subject and her heterozygous sister, with low TBG, showed no significant deviation from that in normal subjects. The k of TBG in the heterozygous mother was slightly below 2 SD of the mean normal, but not as low as in some other patients with various nonthyroidal abnormalities. The DS of TBG was normal in all three, after correction for the strikingly decreased body size of Mi. P. The k and DS of TBG was also normal in an unrelated hemizygous male with low TBG and in two unrelated hemizygous males with high TBG. The D was proportional to the serum concentration of TBG (Fig. 3) . These data indicate, that at least in the four families studied, there were no abnormalities in TBG degradation to explain the observed three types of inherited TBG variations (absence, diminution, and excess). TBG concentration has been previously measured in the serum of three of the subjects studied (Mi. P., P. R., and W. N.) by immunological and competitivebinding techniques, both of which gave identical results (3, 9). The two methods for TBG quantitation in serum identify different sites on the TBG molecule since the TBG-antibody complex does not interfere with subsequent T4 binding to TBG (3) . The affinity of T4 and T8 for TBG from a heterozygous-affected subject, member of a family with TBG deficiency (P. R.), and a hemizygous-affected male with TBG excess, was indistinguishable from normal. During heat inactivation, TBG from P. R. and W. N. exhibited a ti identical to normal persons (3). Finally, serum from TBGdeficient patients does not interfere with T4 binding to TBG from normal persons (10, 11) . Therefore, the data on TBG metabolism, together with the information summarized above, lend further support to our contention that inherited TBG abnormalities in man are due to mutations in a single gene locus controlling TBG synthesis. The total T4 and T8 concentrations in serum, but not the FTI, vary according to the serum concentration of TBG. However, the D of T4 remains normal (Table II and Fig. 4) .
Acquired abnormalities in TBG capacity have also been described. They are occasionally encountered in association with nephrosis, hepatitis, lymphoma, hyperand hypothyroidism, and many other unrelated diseases (13, 14, 34) . In this study we have shown that in one patient with severe acquired decrease in TBG associated with multiple myeloma (M. K.), the ti was considerably shortened and the DS was strikingly increased in the presence of normal D of TBG. (26) and in acute stress (27) .
-e Our results on the TBG metabolism in man are in complete agreement with those of Cavalieri (35) 
